Skip to main content
Log in

Orlistat-Associated Adverse Effects and Drug Interactions

A Critical Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use may be associated with less well known, but sometimes clinically relevant, adverse effects. More specifically, the use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain and faecal spotting. A few cases of serious hepatic adverse effects (cholelithiasis, cholostatic hepatitis and subacute liver failure) have been reported. However, the effects of orlistat on non-alcoholic fatty liver disease are beneficial. Orlistat-induced weight loss seems to have beneficial effects on blood pressure. No effect has been observed on calcium, phosphorus, magnesium, iron, copper or zinc balance or on bone biomarkers. Interestingly, the use of orlistat has been associated with rare cases of acute kidney injury, possibly due to the increased fat malabsorption resulting from the inhibition of pancreatic and gastric lipase by orlistat, leading to the formation of soaps with calcium and resulting in increased free oxalate absorption and enteric hyperoxaluria. Orlistat has a beneficial effect on carbohydrate metabolism. No significant effect on cancer risk has been reported with orlistat.

Orlistat interferes with the absorption of many drugs (such as warfarin, amiodarone, ciclosporin and thyroxine as well as fat-soluble vitamins), affecting their bioavailability and effectiveness.

This review considers orlistat-related adverse effects and drug interactions. The clinical relevance and pathogenesis of these effects is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007 Feb; 63(2): 205–9

    Article  PubMed  Google Scholar 

  2. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001 Jul; 281(1): G16–28

    PubMed  CAS  Google Scholar 

  3. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997 Jun; 21 Suppl. 3: S12–23

    PubMed  CAS  Google Scholar 

  4. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 Jul; 56(1): 82–5

    Article  PubMed  CAS  Google Scholar 

  5. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35(11): 1103–8

    PubMed  CAS  Google Scholar 

  6. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996 Nov; 36(11): 1006–11

    Article  PubMed  CAS  Google Scholar 

  7. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39(1): 41–6

    Article  PubMed  CAS  Google Scholar 

  8. US Food and Drug Administration. FDA approves orlistat for over-the-counter use [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/new01557.html [Accessed 2007 Oct 15]

  9. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005 Nov; 7(6): 699–708

    Article  PubMed  CAS  Google Scholar 

  10. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27(1): 155–61

    Article  PubMed  CAS  Google Scholar 

  11. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4(6): 415–23

    Article  PubMed  CAS  Google Scholar 

  12. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and Cardiovascular risk profile in patients with metabolic 62 syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004 Sep; 20(9): 1393–401

    Article  PubMed  CAS  Google Scholar 

  13. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999 Jan 20; 281(3): 235–42

    Article  PubMed  CAS  Google Scholar 

  14. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 Jun 15; 293(23): 2873–83

    Article  PubMed  CAS  Google Scholar 

  15. O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004 Feb; 5(1): 51–68

    Article  PubMed  Google Scholar 

  16. O’Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5(18): 1–81

    Google Scholar 

  17. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352(9123): 167–72

    Article  PubMed  CAS  Google Scholar 

  18. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998 Apr; 54(2): 125–32

    Article  PubMed  Google Scholar 

  19. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003 Dec; 27(12): 1437–46

    Article  PubMed  CAS  Google Scholar 

  20. Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract]. 16th International Diabetes Federation Congress; 1997 Jul 25–27, Helsinki

  21. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005 Feb; 31(1): 15–22

    Article  PubMed  CAS  Google Scholar 

  22. Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat: case report. NutrJ 2006; 5: 19

    Article  Google Scholar 

  23. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41(12): 2404–8

    Article  PubMed  CAS  Google Scholar 

  24. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007 Jan; 30(1): 27–32

    Article  PubMed  CAS  Google Scholar 

  25. Kim DH, Lee EH, Hwang JC, et al. A case of acute cholestatic hepatitis associated with orlistat [in Korean] [abstract]. Taehan Kan Hakhoe Chi 2002 Sep; 8(3): 317–20

    PubMed  Google Scholar 

  26. Montero JL, Muntane J, Fraga E, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001 Jan; 34(1): 173

    Article  PubMed  CAS  Google Scholar 

  27. Thurairajah PH, Syn WK, Neil DA, et al. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005 Dec; 17(12): 1437–8

    Article  PubMed  Google Scholar 

  28. Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by orlistat? Med Sci Law 2002 Oct; 42(4): 309–12

    PubMed  Google Scholar 

  29. Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med 2006 Aug; 119(8): e7

    Article  PubMed  Google Scholar 

  30. Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007 Feb; 42(2): 139–47

    Article  PubMed  CAS  Google Scholar 

  31. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006 May; 22(5): 873–83

    Article  PubMed  CAS  Google Scholar 

  32. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004 Sep 15; 20(6): 623–8

    Article  PubMed  CAS  Google Scholar 

  33. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of _yclosporine_ fatty liver disease. Clin Gastroenterol Hepatol 2006 May; 4(5): 639–44

    Article  PubMed  CAS  Google Scholar 

  34. Caner M, Dogruman H, Taskin E, et al. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 2005 Dec 31; 48(4): 217–22

    PubMed  CAS  Google Scholar 

  35. O’Donovan D, Horowitz M, Russo A, et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004 Dec; 47(12): 2208–14

    Article  PubMed  CAS  Google Scholar 

  36. Pilichiewicz A, O’Donovan D, Feinle C, et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003 Aug; 88(8): 3829–34

    Article  PubMed  CAS  Google Scholar 

  37. Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord 2003 Dec; 27(12): 1479–85

    Article  PubMed  CAS  Google Scholar 

  38. Fox M, Thumshirn M, Menne D, et al. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. Aliment Pharmacol Ther 2004 Feb 1; 19(3): 311–21

    Article  PubMed  CAS  Google Scholar 

  39. Heck AM, Calis KA, McDuffie JR, et al. Additive gastrointestinal effects with concomitant use of olestra and orlistat. Ann Pharmacother 2002 Jun; 36(6): 1003–5

    Article  PubMed  Google Scholar 

  40. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001 Jul; 25(7): 1095–9

    Article  PubMed  CAS  Google Scholar 

  41. Fox M, Stutz B, Menne D, et al. The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci 2005 Sep; 50(9): 1576–83

    Article  PubMed  CAS  Google Scholar 

  42. Guarino AH. Treatment of intractable constipation with orlistat: a report of three cases. Pain Med 2005 Jul–Aug; 6(4): 327–8

    Article  PubMed  Google Scholar 

  43. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002 Sep; 20(9): 1873–8

    Article  PubMed  CAS  Google Scholar 

  44. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 Jan; 7(1): 47–55

    Article  PubMed  CAS  Google Scholar 

  45. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20(11): 2257–67

    Article  PubMed  CAS  Google Scholar 

  46. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 May; 8(21): iii–iv, 1–182

    PubMed  CAS  Google Scholar 

  47. Zavoral JH.Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998 Dec; 16 (12 Pt 2): 2013–7

  48. Schneider R, Golzman B, Turkot S, et al. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005 Oct; 330(4): 157–60 63

    Article  PubMed  Google Scholar 

  49. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A (2) in obese patients with metabolic syndrome. Atherosclerosis 2007; 193(2): 428–37

    Article  PubMed  CAS  Google Scholar 

  50. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005 Dec; 21(12): 1997–2006

    Article  PubMed  CAS  Google Scholar 

  51. Zanella MT, Uehara MH, Ribeiro AB, et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol 2006 Apr; 50(2): 368–76

    Article  PubMed  Google Scholar 

  52. Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001 Apr 1; 87(7): 827–31

    Article  PubMed  CAS  Google Scholar 

  53. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5(3): 180–8

    Article  PubMed  CAS  Google Scholar 

  54. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21(8): 1288–94

    Article  PubMed  CAS  Google Scholar 

  55. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep; 56(7): 494–9

    PubMed  CAS  Google Scholar 

  56. Derosa G, Cicero AF, Murdolo G, et al. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004 Aug; 17(4): 222–9

    PubMed  CAS  Google Scholar 

  57. Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21(11): 2159–65

    Article  PubMed  CAS  Google Scholar 

  58. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002 Nov 25; 162(21): 2428–35

    Article  PubMed  CAS  Google Scholar 

  59. Kuo CS, Pei D, Yao CY, et al. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2006 Aug; 60(8): 906–10

    Article  PubMed  CAS  Google Scholar 

  60. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005 Mar; 21(3): 457–68

    Article  PubMed  CAS  Google Scholar 

  61. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 Jan 6; 369(9555): 71–7

    Article  PubMed  CAS  Google Scholar 

  62. Persson M, Vitols S, Yue QY. Orlistat associated with hypertension [letter]. BMJ 2000 Jul 8; 321(7253): 87

    Article  PubMed  CAS  Google Scholar 

  63. Johnston GD. Orlistat associated with hypertension: digit preference lays conclusions about orlistat open to doubt [letter]. BMJ 2001 Jan 13; 322(7278): 110

    Article  PubMed  CAS  Google Scholar 

  64. Huber MH. Orlistat associated with hypertension: Roche concludes that there is not evidence of a casual association. BMJ 2001 Jan 13; 322(7278): 110–1

    Article  PubMed  CAS  Google Scholar 

  65. Patten SB. Major depressive episodes and diet pills. Expert Opin Pharmacother 2002 Oct; 3(10): 1405–9

    Article  PubMed  CAS  Google Scholar 

  66. Benazzi F. Depression induced by orlistat (Xenical) [letter]. Can J Psychiatry 2000 Feb; 45(1): 87

    PubMed  CAS  Google Scholar 

  67. Kiortsis DN, Tsouli S, Filippatos TD, et al. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr Metab Cardiovasc Dis. In press

  68. Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005 Oct; 13(10): 1701–8

    Article  PubMed  CAS  Google Scholar 

  69. heleritis CG, Papadimitriou GN, Papageorgiou CC, et al. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 2006; 6: 37

    Article  Google Scholar 

  70. Fernandez-Aranda F, Amor A, Jimenez-Murcia S, et al. Bulimia nervosa and misuse of orlistat: two case reports. Int J Eat Disord 2001 Dec; 30(4): 458–61

    Article  PubMed  CAS  Google Scholar 

  71. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004 Dec; 58(10): 582–7

    Article  PubMed  CAS  Google Scholar 

  72. Acharya NV, Wilton LV, Shakir SA. Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes 2006; 30: 1645–52

    Article  CAS  Google Scholar 

  73. Pritchard JE, Nowson CA, Wark JD. Bone loss accompanying diet-induced or exercise-induced weight loss: a randomised controlled study. Int J Obes Relat Metab Disord 1996 Jun; 20(6): 513–20

    PubMed  CAS  Google Scholar 

  74. Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr 2001 Jun; 131(6): 1694–9

    PubMed  CAS  Google Scholar 

  75. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22(5): 357–62

    PubMed  CAS  Google Scholar 

  76. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001 Aug; 25(8): 1154–60

    Article  PubMed  CAS  Google Scholar 

  77. Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 2004 Aug; 66(2): 676–82

    Article  PubMed  CAS  Google Scholar 

  78. Singh A, Sarkar SR, Gaber LW, et al. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007 Jan; 49(1): 153–7

    Article  PubMed  CAS  Google Scholar 

  79. Courtney AE, O’Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007 Feb; 22(2): 621–3

    Article  PubMed  CAS  Google Scholar 

  80. Packard KA, Wurdeman RL, Reyes AP. Constipation, polyuria, polydipsia, and edema associated with orlistat. Ann Pharmacother 2002 Jul–Aug; 36(7–8): 1168–70

    Article  PubMed  Google Scholar 

  81. Rowe R, Cowx M, Poole C, et al. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 2005 Nov; 21(11): 1885–90

    Article  PubMed  CAS  Google Scholar 

  82. Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006 Feb; 7(2): 211–28

    Article  PubMed  CAS  Google Scholar 

  83. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005 May; 22(5): 612–8

    Article  PubMed  CAS  Google Scholar 

  84. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25(7): 1123–8 64

    Article  PubMed  CAS  Google Scholar 

  85. Xenical® (orlistat) capsules [prescribing information]. Revised 2003 Dec. Roche Laboratories Inc. [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2003/03DEC_PI/Xenical_PI.pdf [Accessed 2007 Oct 15]

  86. Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003 Jun; 26(6): 1667–72

    Article  PubMed  CAS  Google Scholar 

  87. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007 Jan; 66(1): 103–9

    CAS  Google Scholar 

  88. Diamanti-Kandarakis E, Piperi C, Alexandraki K, et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006 Apr; 55(4): 494–500

    Article  PubMed  CAS  Google Scholar 

  89. Czerwienska B, Kokot F, Franek E, et al. Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects [in Polish]. Pol Arch Med Wewn 2004 Dec; 112(6): 1415–23

    PubMed  Google Scholar 

  90. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006 Jun; 7(6): 761–71

    Article  PubMed  CAS  Google Scholar 

  91. Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005 Feb; 90(2): 729–33

    Article  PubMed  CAS  Google Scholar 

  92. Damci T, Yalin S, Balci H, et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004 May; 27(5): 1077–80

    Article  PubMed  CAS  Google Scholar 

  93. Azar ST, Zantout MS. Diabetic ketoacidosis associated with orlistat treatment [letter]. Diabetes Care 2001 Mar; 24(3): 602

    Article  PubMed  CAS  Google Scholar 

  94. Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, et al. Orlistat-induced cutaneous leukocytoclastic vasculitis [letter]. Arthritis Rheum 2002 Oct 15; 47(5): 567

    Article  PubMed  Google Scholar 

  95. Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol 2006 May; 154(5): 1020–1

    Article  PubMed  CAS  Google Scholar 

  96. Morotomi M, Sakaitani Y, Satou M, et al. Effects of a high-fat diet on azoxymethane-induced aberrant crypt foci and fecal biochemistry and microbial activity in rats. Nutr Cancer 1997; 27(1): 84–91

    Article  PubMed  CAS  Google Scholar 

  97. Newmark HL, Yang K, Lipkin M, et al. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis 2001 Nov; 22(11): 1871–5

    Article  PubMed  CAS  Google Scholar 

  98. Thornton Jr WH, MacDonald RS. Dietary fat quantity and composition induce changes in proliferation and membrane lipids in rat colon cells. Ann Nutr Metab 1997; 41(4): 260–8

    Article  PubMed  CAS  Google Scholar 

  99. Garcia SB, Barros LT, Turatti A, et al. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 2006 Aug 28; 240(2): 221–4

    Article  PubMed  CAS  Google Scholar 

  100. Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004 Mar 15; 64(6): 2070–5

    Article  PubMed  CAS  Google Scholar 

  101. Menendez JA, Vellon L, Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood) 2005 Mar; 230(3): 151–4

    CAS  Google Scholar 

  102. Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006 Oct; 20(12): 2027–35

    Article  PubMed  CAS  Google Scholar 

  103. Menendez JA, Vellon L, Lupu R. The antiobesity drug orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 2006 Jan–Feb; 16(1): 219–21

    Article  PubMed  CAS  Google Scholar 

  104. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005 Aug; 16(8): 1253–67

    Article  PubMed  CAS  Google Scholar 

  105. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN): catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 2006 Dec; 7(6): 483–93

    Article  PubMed  CAS  Google Scholar 

  106. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 647–53

    PubMed  CAS  Google Scholar 

  107. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36(2): 152–9

    PubMed  CAS  Google Scholar 

  108. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22(7): 814–22

    Article  PubMed  CAS  Google Scholar 

  109. Holecki M, Zahorska-Markiewicz B, Nieszporek T, et al. The influence of a 3-month weight reduction therapy with orlistat on serum vitamin B12 and folic acid concentration in obese women. Int J Obes (Lond) 2006 Jun; 30(6): 1017–8

    Article  CAS  Google Scholar 

  110. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 659–66

    PubMed  CAS  Google Scholar 

  111. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003 Apr; 37(4): 510–2

    Article  PubMed  Google Scholar 

  112. Zhi J, Moore R, Kanitra L, et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003 Apr; 43(4): 428–35

    Article  PubMed  CAS  Google Scholar 

  113. Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000 Nov 27; 70(10): 1541–2

    Article  PubMed  Google Scholar 

  114. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporine-neoral and orlistat. Am J Kidney Dis 2003 Feb; 41(2): 493–6

    Article  PubMed  Google Scholar 

  115. Nagele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporine concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999 Nov; 55(9): 667–9

    Article  PubMed  CAS  Google Scholar 

  116. Asberg A. Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63(4): 367–78

    Article  PubMed  CAS  Google Scholar 

  117. Barbaro D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002 Mar–Apr; 8(2): 124–6

    PubMed  Google Scholar 

  118. Schnetzler B, Kondo-Oestreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000 Nov 27; 70(10): 1540–1

    Article  PubMed  CAS  Google Scholar 

  119. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42(9): 1011–9

    PubMed  CAS  Google Scholar 

  120. Errasti P, Garcia I, Lavilla J, et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002 Feb; 34(1): 137–9 65

    Article  PubMed  CAS  Google Scholar 

  121. Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000 Apr 13; 342(15): 1141–2

    Article  PubMed  CAS  Google Scholar 

  122. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat [letter]. Epilepsia 2006 Dec; 47(12): 2207

    Article  PubMed  Google Scholar 

  123. Hilger E, Quiner S, Ginzel I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002 Feb; 22(1): 68–70

    Article  PubMed  CAS  Google Scholar 

  124. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain [letter]. Eur Psychiatry 2005 Nov; 20(7): 520

    Article  PubMed  Google Scholar 

  125. Peleg R. Caution when using oral contraceptive pills with Orlistat [letter]. Isr Med Assoc J 2000 Sep; 2(9): 712

    PubMed  CAS  Google Scholar 

  126. Hartmann D, Guzelhan C, Zuiderwijk PB, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50(5): 421–4

    Article  PubMed  CAS  Google Scholar 

  127. Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine [letter]. Clin Oncol (R Coll Radiol) 2005 Sep; 17(6): 492

    Article  CAS  Google Scholar 

  128. Chaikomin R, Russo A, Rayner CK, et al. Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects. Br J Nutr 2006 Nov; 96(5): 883–7

    Article  PubMed  CAS  Google Scholar 

  129. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998 Nov–Dec; 54(9–10): 773–7

    Article  PubMed  CAS  Google Scholar 

  130. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25(6): 1033–41

    Article  PubMed  CAS  Google Scholar 

  131. Pathan MF, Latif ZA, Nazneen NE, et al. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Med Res Counc Bull 2004 Apr; 30(1): 1–8

    PubMed  CAS  Google Scholar 

  132. Sari R, Balci MK, Coban E, et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004 Aug; 28(8): 1059–63

    Article  PubMed  CAS  Google Scholar 

  133. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35(5): 521–5

    PubMed  CAS  Google Scholar 

  134. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 654–8

    PubMed  CAS  Google Scholar 

  135. Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996; 51(1): 87–90

    Article  PubMed  CAS  Google Scholar 

  136. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36(4): 352–5

    PubMed  CAS  Google Scholar 

  137. Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003 Apr; 25(4): 1107–22

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Some of the authors have given talks, attended conferences and participated in trials and advisory boards sponsored by various pharmaceutical companies including Roche.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Moses S. Elisaf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filippatos, T.D., Derdemezis, C.S., Gazi, I.F. et al. Orlistat-Associated Adverse Effects and Drug Interactions. Drug-Safety 31, 53–65 (2008). https://doi.org/10.2165/00002018-200831010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831010-00005

Keywords

Navigation